Riding high on early clinical trial results showing that its neuromodulation headset can improve memory and cognition and slow the deterioration of white matter in the brains of people with ...

- Long-term, daily proprietary gamma sensory stimulation was shown to be safe and well tolerated; treatment integrated well into subjects' daily lives. - Pivotal trials will launch this year to ...

As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...

Top-tier investor syndicate led by FoundersX Ventures, with participation from all existing investors and new investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and ...

Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation ...

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...

All products featured on WIRED are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. Learn more. New ...

Alzheimer's disease is a complicated and debilitating disease that has no cure. One startup is testing whether a "disco" of light and sound can slow the disease in patients. Cognito Therapeutics ...